Researchers assess the heterogeneous effects of childhood adversity on disease biomarkers and health conditions in adulthood.
Editas sells future CRISPR license fees; Plus, news about Oncolytics Biotech
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS